Oral Contraceptive Treatment for Rheumatoid Arthritis: An Open Study in 10 Female Patients

Publisher Website
Google Scholar
Abstract
Ten female patients (median age 37 years, range 23-45) with active rheumatoid arthritis (RA) (nine seropositive, one seronegative, seven erosive, three non-erosive) were treated during 6 months with one of the earlier, i.e. higher dosed, oral contraceptives (Lyndiol®, each tablet containing 2.5 mg lynestrenol and 0.05 mg ethinyloestradiol). None of the patients had been previously treated with a disease modifying drug. In one patient therapy with Lyndiol® was stopped within 14 days after the start because of vomiting. Three out of the remaining nine patients stopped the therapy after 3 months because of inefficacy. Erythrocyte sedimentation rate (ESR) deteriorated during the study. Except for the number of swollen joints no clinical or laboratory parameters improved. We conclude that Lyndiol® has no disease modifying effect in rheumatoid arthritis.

This publication has 0 references indexed in Scilit: